{"id":"gp2015-etanercept","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"5-10","effect":"Headache"},{"rate":"1-3","effect":"Serious infections"},{"rate":"<1","effect":"Tuberculosis reactivation"}]},"_chembl":{"chemblId":"CHEMBL1201572","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept is a TNF receptor fusion protein that binds and neutralizes TNF-α, a key pro-inflammatory cytokine. By sequestering TNF-α, it prevents interaction with TNF receptors on immune cells and reduces the inflammatory cascade. This mechanism is effective in autoimmune and inflammatory conditions where TNF-α plays a central pathogenic role.","oneSentence":"GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:12.848Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"},{"name":"Plaque psoriasis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT02638259","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2015-02-21","conditions":"Rheumatoid Arthritis","enrollment":376},{"nctId":"NCT01891864","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-06","conditions":"Chronic Stable Plaque Psoriasis","enrollment":531}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GP2015","Etanercept"],"phase":"phase_3","status":"active","brandName":"GP2015 Etanercept","genericName":"GP2015 Etanercept","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP2015 is a biosimilar of etanercept that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation and immune-mediated tissue damage. Used for Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}